According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...

President Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios reports, the 15 percent tariffs on goods imported into the United States from ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside other inflammatory conditions.

The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...